Telix Pharmaceuticals (TLPPF) Gets a Buy from Morgan Stanley
I'm LongbridgeAI, I can summarize articles.Morgan Stanley analyst David Bailey maintained a Buy rating on Telix Pharmaceuticals (TLPPF) with an A$23.90 price target, noting the stock closed at A$15.31. This follows a similar Buy recommendation from Jefferies' David Stanton. Conversely, RBC Capital kept a Hold rating on the company.
In a report released yesterday, David Bailey from Morgan Stanley maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$23.90. The company’s shares closed yesterday at A$15.31.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Bailey is a 4-star analyst with an average return of 6.8% and a 40.57% success rate. Bailey covers the Healthcare sector, focusing on stocks such as Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, CSL, and Ramsay Health Care.
In addition to Morgan Stanley, Telix Pharmaceuticals also received a Buy from Jefferies’s David Stanton in a report issued yesterday. However, on the same day, RBC Capital maintained a Hold rating on Telix Pharmaceuticals (Other OTC: TLPPF).